Human brain imaging clinical trials are already underway for a proprietary cannabinoid formulation to treat a major condition.
The testing performed by MA Analytics will protect consumers from contaminants, chemicals, and other impurities ensuring that the end consumer is getting the best possible product.
Keystone State Testing is leading the way in PA and has also received accreditation from Americans for Safe Access.
Results indicate that the cannabinoid compounds have different apoptotic - or cell-killing effects - depending on the dosage, type of cancer and the compound configuration.
Two Vitalis Q-90 CO2 extraction machines have been added to existing facilities to increase their monthly processing capacity to 6000kg of cannabis.
This topic has been debated by many experts and it remains contested whether a cause-and-effect relationship between smoking cannabis and schizophrenia truly exists.